[ad_1]
March Jul. 31 2018 – 12:15 AM
Parkinson's is caused by a lack of dopamine made by brain cells and researchers have long hoped to use stem cells to restore normal production of the neurotransmitter chemical.
Clinical trials come after researchers from Kyoto University in Japan successfully used induced pluripotent stem cells (iPS) to restore functional brain cells in monkeys last year.
iPS cells are made by removing mature cells from an individual – often from skin or blood – and reprogramming them as embryonic stem cells. "This will be the first clinical trial in the world using iPS cells on Parkinson's disease," said Jun Takahashi, a professor at the Kyoto University's Research and Application Center on iPS Cells.
The center is led by Shinya Yamanaka, who in 2012 shared a Nobel Prize in Medicine with a British scientist, John Gurdon, for the discovery that adult cells can be turned into embryonic-like cells
". We intend to continue conducting our research carefully, but expeditiously, in coordination with the Kyoto University Hospital, so that a new treatment using iPS cells is brought to the patients most quickly, "Yamanaka said in a statement. that the clinical trial uses iPS cells rather than human embryonic cells means that the treatment would be acceptable in countries like Ireland and much of Latin America, where embryonic cells are prohibited .
Sumitomo Dainippon Pha Rma Co Ltd stated that it aims to manufacture and start selling cell medicine based on clinical trial data by the end of the year ending in March 2023. [19659003] The company said, however, the target is his and not a shared goal with Kyoto University
REUTERS
[ad_2]
Source link
